BIIB
BIOGEN INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$240.98
−0.87%Year over year
Reported trailing growth
- Revenue
- -0.5%
- EBITDA
- -42.2%
- EBIT
- -47.1%
- EPS
- -45.9%
- Free cash flow
- +59.9%
- Operating cash flow
- +36.0%
Forward estimates
Based on analyst estimates
- Revenue
- +6.1%
- EBITDA
- +90.2%
- EPS
- +170.1%
Three-year CAGR
- Revenue
- -1.2%
- EBITDA
- -5.9%
- EBIT
- -13.4%
- Net income
- -24.8%
- EPS
- -25.0%
- Free cash flow
- +21.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026